

Breast Milk Fatty Acids May Link Innate and Adaptive Immune Regulation: Analysis of Soluble CD14, Prostaglandin E₂, and Fatty Acids

KIRSI LAITINEN, ULLA HOPPU, MARI HÄMÄLÄINEN, KAISA LINDERBORG, EEVA MOILANEN, AND ERIKA ISOLAURI

Department of Paediatrics [K.La., E.I.], Turku University Central Hospital, 20521 Turku, Finland; Functional Foods Forum [K.La., U.H.], Department of Biochemistry and Food Chemistry [K.La., U.H., K.Li.], Department of Paediatrics [E.I.], University of Turku, 20014 Turku, Finland; The Immunopharmacology Research Group [M.H., E.M.], University of Tampere Medical School and Tampere University Hospital, 33014 Tampere, Finland

ABSTRACT: In addition to its role in sensing intraluminal microbial antigens, soluble (s)CD14 may regulate immune responses by its lesser known function as a lipid carrier with possible influences in the production of fatty acid-derived eicosanoids. We investigated the interrelations of fatty acids, prostaglandin E₂ (PGE₂), and sCD14 and their role in infant atopic eczema during the first year of life. Serum and breast milk samples from mothers and serum samples from their infants were collected at infant's age 3 mo and analyzed for sCD14 and PGE₂ concentrations and for fatty acid compositions. The main correlation of sCD14 was with arachidonic acid (20:4n-6) (AA). Dihomo- γ -linolenic acid (20:3n-6) (DHGLA) and the ratio of n-6 to n-3 fatty acids correlated positively and docosahexaenoic acid (22:6n-3) (DHA) and sum of n-3 fatty acid negatively with PGE₂ in mother's serum and linoleic acid (LA) negatively with PGE₂ in breast milk. Soluble CD14 tended to be higher and LA, total polyunsaturated fatty acid (PUFA), and sum of n-6 fatty acids were lower in breast milk received by infants with atopic eczema compared with those without. These results suggest that fatty acids contribute to the regulation of innate and adaptive immune responses and link intraluminal exposures, mother's diet, and microbes. (*Pediatr Res* 59: 723-727, 2006)

Characteristic dietary habits in Western societies have constantly been linked to chronic diseases such as diabetes, cardiovascular diseases, and more recently allergic diseases. The accumulating data point to the early fetal period and infancy as the critical phase (1). Specific dietary compounds, including fatty acids and probiotics, have been exploited in the development of prophylactic and therapeutic interventions, the effects ensuing through their immunomodulatory properties (2). For the infant, the effects are drawn together by outstanding breast milk composition, providing not only nourishment but also signals for the maturation of the adaptive immune responses considered imperative with regard to the risk of diseases (3).

Although the major function described for soluble (s)CD14, a pattern recognition receptor, is binding of lipopolysaccha-

rides and thus antimicrobial host defense (4), its binding specificity is not restricted to bacteria. It also binds phospholipids, thus providing a lipid transfer system (5). This innovative function of sCD14 may prove significant, with a potential to modify immune events through phospholipid polyunsaturated fatty acids (PUFAs). Both dietary and cellular fatty acids are evidently important immune regulators via their derivative eicosanoids, particularly PGE₂ and consequent cytokine responses, as suggested in allergic disease (6). The concentration of sCD14 in breast milk has been shown to be up to 20-fold higher than in serum (7), thus providing infants with an external source of sCD14 with potential health benefits as previously observed in allergic disease (8). Experimental studies have linked sCD14 to phospholipid transport in blood (5,9) and a positive correlation between sCD14 and n-3 fatty acids in breast milk has been observed (10), but no studies have examined the relationships, if any, among sCD14, PUFAs, and their derivative eicosanoids.

We sought here to investigate the lesser known function of sCD14 as a lipid carrier and thus the possible immunomodulatory route by evaluating the associations prevailing between serum and breast milk sCD14, fatty acid compositions, and PGE₂. We also explored the associations of these immunomodulatory factors between mother's or infant's serum and breast milk and their role in atopic eczema in the infant.

METHODS

Subjects and study design. A cohort of mothers ($n = 38$) with atopic disease (asthma, atopic eczema, allergic rhinitis) and their infants were followed from the end of gestation until the infant's age of 1 y (11). Infants were clinically examined at 1, 3, 6, and 12 mo of age. Their weights and heights were measured and hospital records examined for birth data. Atopic eczema was diagnosed as the presence of pruritus, facial and/or extensor involvement, and chronic course of at least 1 mo (12) with positive skin prick test result measured as previously described (11). The study was approved by the Ethical Committee of the Hospital District of South-West Finland, and informed written consent was obtained from the mothers.

Abbreviations: AA, arachidonic acid, 20:4n-6; DHA, docosahexaenoic acid (22:6n-3); DHGLA, dihomomath-\gamma\text{-linolenic acid, 20:3n-6; IQR, interquartile range; LA, linoleic acid, 18:2n-6; PGE₂, prostaglandin E₂; PUFA, polyunsaturated fatty acid

Received September 20, 2005; accepted December 6, 2005.
Correspondence: Kirsi Laitinen, Ph.D., University of Turku, Itäinen Pitkätatu 4A, 5th floor, 20520 Turku, Finland; e-mail: kirsi.laitinen@utu.fi
Supported by the Academy of Finland.

DOI: 10.1203/01.pdr.0000203158.31452.9e

Analytical methods. Serum samples from mothers and infants and breast milk samples were collected at the infants' age of 3 mo. Samples were stored at -70°C until analyzed. For the analysis of sCD14, the serum or breast milk samples were thawed, mixed, and centrifuged at $14926 \times g$ for 10 min at room temperature to separate fat and cells from whey. The concentration of sCD14 (detection limit: 125 pg/mL) in serum or in whey of breast milk were determined using commercial sandwich enzyme-linked immunosorbent assay (ELISA) specific to these molecules (R&D Systems Europe Ltd., Abingdon, UK) as recommended by the manufacturer. For PGE₂ analysis, the samples were first purified by minicolumns (RPN 1900, Amersham Biosciences, Buckinghamshire, UK) and PGE₂ (detection limit: 3.1 pg/mL) was then measured by radioimmunoassay using reagents from Amersham Biosciences (RPA530).

Serum phospholipid fatty acid compositions of mother and infant and the fatty acid composition of breast milk were analyzed. Total lipids in the samples were extracted with chloroform:methanol 2:1 vol/vol (13). Polar lipids were separated from neutral lipids by solid phase extraction with silica columns (14). As samples were assumed not to contain significant amounts of FFA or mono- or diacylglycerols, the polar lipid fraction was taken to consist of phospholipids. Fatty acid methyl esters were prepared from breast milk lipids and the isolated polar lipid fraction with boron trifluoride and analyzed by gas chromatography (PerkinElmer AutoSystem, Norwalk, CT), with DB-23 column (60 m \times 0.25 mm i.d., 0.25 μm film thickness; Agilent Technologies, Palo Alto, CA). Diheptadecanoylphosphatidylcholine (Sigma Chemical Co.–Aldrich, St. Louis, MO) was used as an internal standard in plasma samples and triheptacosanoic acid (Sigma Chemical Co.–Aldrich) in breast milk samples. Breast milk total triacylglycerol concentration was determined in relation to the internal standard.

Statistics. Values are reported as medians with interquartile range (IQR) and as means with ranges for descriptive subject characteristics. Sufficient amounts of breast milk were available from 38 mothers and serum from 35 mothers and 22 infants for all laboratory analyses. Significant correlations were analyzed by Spearman's rank correlation coefficient (ρ) and differences between infants with and without atopic eczema by Mann-Whitney *U* test. All statistical analyses were performed on SPSS for Windows (version 12.0.1; SPSS Inc., Chicago, IL).

RESULTS

All infants were born full-term (mean, 39 wk; range, 37–42 wk of gestation) with a mean birth weight of 3590 g (range, 2730–4890) g and a height of 51 cm (range, 47–55) and were being exclusively or predominantly breast-fed at the age of 3 mo. Atopic eczema with chronic or recurrent eczema from 1 to 12 mo of age and a positive skin prick test result for at least one sensitizing antigen was observed in 29% of the infants (11 of 38 infants).

Mother's and infant's serum and breast milk sCD14 and PGE₂ concentrations and fatty acid compositions are shown in Table 1. The total triacylglycerol content in breast milk was 33 g/L (range, 24 to 54). Associations between mother's serum and breast milk composition were evaluated by correlations. Neither mother's serum sCD14 [$\rho = -0.13$, not significant (NS)] nor PGE₂ ($\rho = 0.21$, NS) correlated with those of breast milk. Of the PUFAs in the mother's serum, α -linolenic acid (18:3n-3; $\rho = 0.44$, $p = 0.009$), eicosapentaenoic acid (20:5n-3; $\rho = 0.94$, $p < 0.001$, DHA (22:6n-3; $\rho = 0.89$, $p < 0.001$), AA ($\rho = 0.56$, $p = 0.001$), sum of n-3 fatty acids ($\rho = 0.46$, $p = 0.006$), and the ratio of n-6 to n-3 fatty acids ($\rho = 0.51$, $p = 0.002$) correlated with those in breast milk.

The relationships between mother and infant were examined by calculating correlations for compositions between breast milk and infant's serum and between mother's and infant's serum. Mother's serum sCD14 ($\rho = 0.48$, $p = 0.003$; Fig. 1) and PGE₂ ($\rho = 0.60$, $p < 0.001$) correlated positively with those in infant's serum, and additionally an inverse correlation was detected between mother's serum PGE₂ and infant's serum DHA ($\rho = -0.44$, $p = 0.03$) and the sum of PUFAs ($\rho = -0.43$, $p = 0.04$). Breast milk sCD14 or PGE₂ did not correlate with infant's serum composition, but breast milk PUFA composition was reflected in the infant's serum, as correlations were observed in breast milk for DHGLA (20:3n-6; $\rho = 0.45$, $p = 0.02$), AA ($\rho = 0.51$, $p = 0.01$), eicosapentaenoic acid ($\rho = 0.84$, $p < 0.001$), DHA ($\rho = 0.83$, $p < 0.001$), sum of PUFAs ($\rho = 0.49$, $p = 0.01$), and ratio of n-6 to n-3 fatty acids ($\rho = 0.45$, $p = 0.02$) with those in infant's serum.

The hypothesis on the relationships between sCD14, PGE₂, and fatty acids was evaluated by calculating their correlations within each medium. In mother's serum, sCD14 correlated positively with AA ($\rho = 0.43$, $p = 0.01$, $n = 35$) and negatively with 20:2n-6 ($\rho = -0.48$, $p = 0.003$) of the fatty acids, whereas no correlation was detected with PGE₂ ($\rho =$

Table 1. Breast milk and mother's and infant's serum sCD14 ($\mu\text{g/mL}$) and PGE₂ (pg/mL) concentrations and fatty acid composition (% of total fatty acids)

	Breast milk ($n = 38$)		Mother's serum ($n = 35$)		Infant's serum ($n = 24$)	
	Median	IQR	Median	IQR	Median	IQR
sCD14	9.0	7.1–11.8	1.3	1.1–1.4	1.0	0.9–1.13
PGE ₂	464	312–868	63	36–145	61	35–159
Fatty acid						0.19–0.29
18:3n-3	1.72	1.47–2.32	0.38	0.32–0.49	0.21	9–0.29
20:5n-3	0.11	0.09–0.16	2.00	1.46–2.66	0.98	0.78–1.47
22:6n-3	0.31	0.19–0.42	4.05	2.96–4.79	6.02	4.56–6.77
sum n-3	2.41	1.99–2.80	6.32	5.22–8.06	7.39	5.73–8.43
18:2n-6	9.59	8.89–11.19	21.69	19.72–23.31	18.89	17.94–20.88
18:3n-6	0.09	0.07–0.12	0.08	0.06–0.11	0	0–0.05
20:2n-6	0.21	0.19–0.22	0.43	0.39–0.47	0.41	0.38–0.46
20:3n-6	0.28	0.26–0.33	3.03	2.50–3.51	2.97	2.56–3.19
20:4n-6	0.35	0.32–0.38	8.55	8.02–9.19	10.43	9.12–11.78
sum-6	10.55	9.81–12.13	34.26	32.12–35.06	33.17	32.32–34.31
sum n-6/sum n-3	4.54	3.87–5.16	5.59	4.09–6.56	4.50	3.85–5.98
Total polyunsaturated fatty acids	12.81	11.81–14.96	40.34	39.69–41.44	40.59	40.07–41.05

The results are presented as median and IQR.




Figure 1. Association between mother's and infant's serum soluble (s)CD14 concentration ($n = 22$). Spearman rank correlation coefficient $\rho = 0.48$, $p = 0.003$. Regression equation by linear regression analysis.

0.03, NS). PGE₂ in turn correlated positively with DHGLA ($\rho = 0.44$, $p = 0.008$) and the ratio of sum of n-6 to the sum of n-3 fatty acids ($\rho = 0.41$, $p = 0.01$), and negatively with DHA ($\rho = -0.44$, $p = 0.009$) and sum of n-3 fatty acid ($\rho = -0.44$, $p = 0.008$) in mother's serum. In infant's serum, no correlations between sCD14 and PGE₂ or fatty acids were detected, but PGE₂ correlated positively with DHGLA ($\rho = 0.42$, $p = 0.04$, $n = 24$). In breast milk, a negative correlation was found between sCD14 and γ -linolenic acid (18:3n-6; $\rho = -0.48$, $p = 0.002$). PGE₂ in breast milk was inversely correlated with LA (linoleic acid) (18:2n-6; $\rho = -0.33$, $p = 0.04$). The total triacylglycerol content in breast milk correlated with both sCD14 ($\rho = 0.360$, $p = 0.026$) and PGE₂ ($\rho = 0.387$, $p = 0.022$).

Differences in the concentrations of sCD14 and PGE₂ and fatty acid composition were evaluated between infants with and without atopic disease. There was a tendency for sCD14 to be higher in breast milk received by infants with atopic eczema [11.3 $\mu\text{g/mL}$ (IQR, 8.3–14.7)] compared with those without [8.7 $\mu\text{g/mL}$ (IQR, 6.8–10.7), $p = 0.05$, Fig. 2]. No differences were observed either for mother's or infant's serum sCD14 or PGE₂ in breast milk or in mother's or in infant's serum according to infant's atopic disease status (data not shown). LA [9.1 (IQR, 8.1–10.2) versus 10.3 (IQR, 9.7–11.0), $p = 0.04$], total PUFA [12.4 (IQR, 10.8–14.0) versus 13.9 (IQR, 13.0–14.8), $p = 0.04$] and sum of n-6 fatty acids [10.1 (IQR, 9.0–11.2) versus 11.3 (IQR, 10.6–12.0), $p = 0.04$] were lower in breast milk received by infants with atopic eczema compared with those without, whereas no differences were observed between the groups in other PUFAs in breast milk or PUFAs in infant's serum (data not shown).




Figure 2. Soluble (s)CD14 concentrations in breast milk received by infants with ($n = 11$) and without ($n = 27$) atopic eczema. Difference between the groups $p = 0.05$, Mann-Whitney U test.

DISCUSSION

The significance of diet in early infancy for the maturing immune system to restrain disease and to ensure normal growth and development has received increasing attention with knowledge accruing. We now investigated the associations among breast milk and serum sCD14, PGE₂, and fatty acids and also differences in them between infants with and without atopic eczema. Our results show that sCD14 and PGE₂ levels are reflected by fatty acid compositions and that these are linked to the manifestation of atopic eczema in the infant.

Our finding of a correlation between mother's and infant's serum sCD14 support the previous conception that the serum sCD14 concentration is regulated by genetic variation (15,16). No associations were observed between mother's serum and breast milk sCD14, which was expected, as a mammary epithelial cell line has been shown to produce sCD14 (7). Nevertheless, the fatty acid composition in mother's serum was associated with that of breast milk and, further, breast milk fatty acid composition was reflected in the infant's serum (17–20). The breast milk composition could thus be amenable to maternal dietary interventions, also suggested previously (10,21).

What would be the basis for suggested relationship between sCD14 and PGE₂? In addition to its well-known function in binding of lipopolysaccharides, sCD14 also facilitates the transport of phospholipids and hence the release of fatty acids (5,9), possibly influencing the production of PUFA-derived eicosanoids, particularly AA-derived PGE₂ with properties engaging in immune regulation via immunoglobulin E production (22). Such a view is supported by the result in the present study showing an association between sCD14 with AA and with 20:2n-6 in mother's serum. The association was not, however, seen in infant's serum or in breast milk, but sCD14 in breast milk was positively associated with total breast milk triacylglycerols. Further, although bearing in mind

the small proportion of γ -linolenic acid detected in the samples, an inverse association between breast milk sCD14 and γ -linolenic acid was detected, possibly reflecting the rapid turnover of this precursor fatty acid for AA. Such an interrelation among the fatty acids and sCD14 suggests that sCD14 may regulate the transport of fatty acids, as shown in an experimental study (5) and would thus affect the production of immunomodulatory eicosanoids, giving further insight into the regulation of T helper 3 or T regulatory cells via fatty acids and PGE₂ (22). However, no evidence of an association between sCD14 and PGE₂ was detected, possibly reflecting the excessively indirect mode of assessing the association. Nevertheless, PGE₂ was found to correlate positively with n-6 fatty acids and negatively with n-3 fatty acids, as was expected (23,24). Although no associations between sCD14 and n-3 fatty acids were detected in the present study, a positive correlation has previously been observed between breast milk sCD14 and docosapentaenoic acid (22:5n-3) (10).

The present study showed that the fatty acid composition of breast milk influences the health status of the infant, as LA, the sum of n-6 fatty acids, and PUFAs were lower in breast milk received by infants with atopic eczema compared with those without. Furthermore, sCD14 tended to be higher in breast milk received by infants with atopic eczema. There are previous studies on record both supporting and conflicting with our data (25–28). The immunologic functions of fatty acids in allergy are generally seen to be proinflammatory because n-6 fatty acids may result in increased immunoglobulin E production (6), and against this background, n-3 fatty acid supplementations have been initiated (29,30). According to experimental studies, the availability of sCD14 appears to be rate limiting for the amount of lipid passing out from cell membranes to media (9). Considering our results on higher sCD14 in breast milk received by infants with atopic eczema and also the previous observation of a higher serum sCD14 concentration in atopic mothers compared with those without (31), it may be that the patients with allergic disease have a reduced capacity to exploit sCD14. Alternatively, breast milk sCD14 levels may play a role in mediating responses to beneficial bacteria (7), and the resultant reduced availability of sCD14 via breast milk would increase the risk of infant's eczema, as previously reported (8). Further, sCD14 has been associated with inhibition of immunoglobulin E production (15,32). However, in keeping with our results, no association between serum sCD14 and allergic disease status of the child has been observed (8,31), but higher cord blood sCD14 levels in children with transient atopy during a 5-y follow-up (8) and lower sCD14 levels in atopic children have been reported (33).

The present results on the role of breast milk sCD14 in atopic disease and on the associations of sCD14 with fatty acids appear to confound those of previous studies (8,10). Here, infant's atopic eczema was defined by the presence of chronic eczema with a positive skin prick test result and all mothers had allergic disease, deviating from findings of previous work (8,33), the distinct immunologic characteristics possibly explaining the results. Further, we did not modify mother's diet, in contrast to a previous study (10) in which the breast milk composition may have been influenced by fish oil

supplementation. The resultant increase in cellular levels of n-3 fatty acids could give rise to counterregulation of n-6 fatty acids (34). Indeed, fish oil supplementation has been shown to reduce PGE₂ levels (35), and although n-3 fatty acids are generally considered beneficial for health due to their anti-inflammatory effects (36), adverse effects have recently been reported (37,38). In succession, n-6 fatty acids may exhibit a beneficial role in allergic disease via the effects of T helper 3 or T regulatory cells and thus via anti-inflammatory transforming growth factor β_2 and interleukin-10 production (22). In contrast to differences in breast milk composition, neither the infant's serum fatty acid composition nor sCD14 or PGE₂ concentrations differed according to the infant's atopic eczema status. This emphasizes the importance of the first-line defense of the gastrointestinal tract in developing diseases like allergy. Particular importance for the maturation of the innate immune defense system would appear to attach to breast milk composition, providing the infant with an external source of immunomodulatory factors (3).

Our study showed that fatty acids are correlated with the potential immunomodulators sCD14 and PGE₂ and that their composition in breast milk is related to the infant's atopic eczema. Further, intestinal microbes (39) and potential immunomodulators, probiotics, are suggested to exert their effects via similar signaling pathways (40,41). Host-microbe interaction, which is mediated through molecules like CD14, is important for the first-line host defense against allergic, infectious, and inflammatory diseases (42,43). An external source of sCD14 provided via breast milk may be of particular importance providing stimulus for the gut immune system (7). In view of the aberrant barrier functions of the skin epithelium and gut mucosa in children with atopic eczema, the joint effects of nutrients and probiotics promoting the defense mechanisms may confer an important therapeutic advantage (2). This concept calls for more precise analysis of joint effects, particularly when supplementing the diet is becoming an increasingly widespread practice. We advocate the concept that maternal dietary modification offers an intervention target to modulate the infant's innate immune system to benefit health. The results of the study have shown that dietary fatty acids are an important target, the potential immunomodulatory effects of which ensue through sCD14 and PGE₂.

Acknowledgments. We thank Satu Sivula for laboratory assistance and Dr. Minna Rinne and Johanna Hvitfelt-Koskelainen for their contribution to contacts with the study subjects and Robert MacGilleon for revision of the English text.

REFERENCES

1. Barker DJ 2004 The developmental origins of chronic adult disease. *Acta Paediatr Suppl* 446:26–33
2. Laitinen K, Kalliomäki M, Poussa T, Lagström H, Isolauri E 2005 Evaluation of diet and growth in children with and without atopic eczema: follow-up study from birth to 4 years. *Br J Nutr* 94:565–574
3. Field CJ 2005 The immunological components of human milk and their effect on immune development in infants. *J Nutr* 135:1–4
4. Goldblum SE, Grann TW, Ding X, Pugin J, Tobias PS 1994 Lipopolysaccharide (LPS)-binding protein and soluble CD14 function as accessory molecules for LPS-induced changes in endothelial barrier function, in vitro. *J Clin Invest* 93:692–702

5. Yu B, Hailman E, Wright SD 1997 Lipopolysaccharide binding protein and soluble CD14 catalyze exchange of phospholipids. *J Clin Invest* 99:315–324
6. Black PN, Sharpe S 1997 Dietary fat and asthma: is there a connection? *Eur Respir J* 10:6–12
7. Labeta MO, Vidal K, Nores JE, Arias M, Vita N, Morgan BP, Guillemot JC, Loyaux D, Ferrara P, Schmid D, Affolter M, Borysiewicz LK, Donnet-Hughes A, Schiffrin EJ 2000 Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. *J Exp Med* 191:1807–1812
8. Jones CA, Holloway JA, Popplewell EJ, Diaper ND, Holloway JW, Vance GH, Warner JA, Warner JO 2002 Reduced soluble CD14 levels in amniotic fluid and breast milk are associated with the subsequent development of atopy, eczema, or both. *J Allergy Clin Immunol* 109:858–866
9. Sugiyama T, Wright SD 2001 Soluble CD14 mediates efflux of phospholipids from cells. *J Immunol* 166:826–831
10. Dunstan JA, Roper J, Mitoulas L, Hartmann PE, Simmer K, Prescott SL 2004 The effect of supplementation with fish oil during pregnancy on breast milk immunoglobulin A, soluble CD14, cytokine levels and fatty acid composition. *Clin Exp Allergy* 34:1237–1242
11. Hoppu U, Rinne M, Salo-Väänänen P, Lampi AM, Piironen V, Isolauri E 2005 Vitamin C in breast milk may reduce the risk of atopy in the infant. *Eur J Clin Nutr* 59:123–128
12. Hanifin JM 1991 Atopic dermatitis in infants and children. *Pediatr Clin North Am* 38:763–789
13. Folch J, Lees M, Sloane Stanley GH 1957 A simple method for the isolation and purification of total lipides from animal tissues. *J Biol Chem* 226:497–509
14. Hamilton JG, Comai K 1988 Rapid separation of neutral lipids, free fatty acids and polar lipids using prepacked silica Sep-Pak columns. *Lipids* 23:1146–1149
15. Baldini M, Lohman IC, Halonen M, Erickson RP, Holt PG, Martinez FD 1999 A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. *Am J Respir Cell Mol Biol* 20:976–983
16. Guerra S, Carla Lohman I, LeVan TD, Wright AL, Martinez FD, Halonen M 2004 The differential effect of genetic variation on soluble CD14 levels in human plasma and milk. *Am J Reprod Immunol* 52:204–211
17. Duchén K, Casas R, Fagerås-Böttcher M, Yu G, Björkstén B 2000 Human milk polyunsaturated long-chain fatty acids and secretory immunoglobulin A antibodies and early childhood allergy. *Pediatr Allergy Immunol* 11:29–39
18. Elias SL, Innis SM 2001 Infant plasma trans, n-6, and n-3 fatty acids and conjugated linoleic acids are related to maternal plasma fatty acids, length of gestation, and birth weight and length. *Am J Clin Nutr* 73:807–814
19. Glew RH, Huang YS, Vander Jagt TA, Chuang LT, Bhatt SK, Magnussen MA, Vander Jagt DJ 2001 Fatty acid composition of the milk lipids of Nepalese women: correlation between fatty acid composition of serum phospholipids and melting point. *Prostaglandins Leukot Essent Fatty Acids* 65:147–156
20. Kankaanpää P, Nurmela K, Erkkilä A, Kalliomäki M, Holmberg-Marttila D, Salminen S, Isolauri E 2001 Polyunsaturated fatty acids in maternal diet, breast milk and serum lipid fatty acids of infants in relation to atopy. *Allergy* 56:633–638
21. Helland IB, Saugstad OD, Smith L, Saarem K, Solvoll K, Ganes T, Drevon CA 2001 Similar effects on infants of n-3 and n-6 fatty acids supplementation to pregnant and lactating women. *Pediatrics* 108:E82–
22. Newberry RD, Stenson WF, Lorenz RG 1999 Cyclooxygenase-2-dependent arachidonic acid metabolites are essential modulators of the intestinal immune response to dietary antigen. *Nat Med* 5:900–906
23. Brash AR 2001 Arachidonic acid as a bioactive molecule. *J Clin Invest* 107:1339–1345
24. Laiho K, Lampi AM, Hamalainen M, Moilanen E, Piironen V, Arvola T, Syrjanen S, Isolauri E 2003 Breast milk fatty acids, eicosanoids and cytokines in mothers with and without allergic disease. *Pediatr Res* 53:642–647
25. Wright S, Bolton C 1989 Breast milk fatty acids in mothers of children with atopic eczema. *Br J Nutr* 62:693–697
26. Businco L, Ioppi M, Morse NL, Nisini R, Wright S 1993 Breast milk from mothers of children with newly developed atopic eczema has low levels of long chain polyunsaturated fatty acids. *J Allergy Clin Immunol* 91:1134–1139
27. Duchon K, Yu G, Björkstén B 1998 Atopic sensitization during the first year of life in relation to long chain polyunsaturated fatty acid levels in human milk. *Pediatr Res* 44:478–484
28. Reichardt P, Muller D, Posselt U, Vorberg B, Diez U, Schlink U, Reuter W, Borte M Leipzig Allergy Risk Children's Study Group 2004 Fatty acids in colostrum from mothers of children at high risk of atopy in relation to clinical and laboratory signs of allergy in the first year of life. *Allergy* 59:394–400
29. Thien FC, Woods RK, Abramson MJ 2002 Dietary marine fatty acids (fish oil) for asthma in adults and children. *Cochrane Database Syst Rev*:CD001283
30. van Gool CJ, Zeegers MP, Thijs C 2004 Oral essential fatty acid supplementation in atopic dermatitis - a meta-analysis of placebo-controlled trials. *Br J Dermatol* 150:728–740
31. Holmlund U, Höglind A, Larsson AK, Nilsson C, Sverremark Ekström E 2003 CD14 and development of atopic disease at 2 years of age in children with atopic or non-atopic mothers. *Clin Exp Allergy* 33:455–463
32. Arias MA, Rey Nores JE, Vita N, Stelter F, Borysiewicz LK, Ferrara P, Labeta MO 2000 Cutting edge: human B cell function is regulated by interaction with soluble CD14: opposite effects on IgG1 and IgE production. *J Immunol* 164:3480–3486
33. Zdolsek HA, Jenmalm MC 2004 Reduced levels of soluble CD14 in atopic children. *Clin Exp Allergy* 34:532–539
34. Lee TH, Hoover RL, Williams JD, Sperling RI, Ravalese 3rd J, Spur BW, Robinson DR, Corey EJ, Lewis RA, Austen KF 1985 Effect of dietary enrichment with eicosapentaenoic and docosahexaenoic acids on in vitro neutrophil and monocyte leukotriene generation and neutrophil function. *N Engl J Med* 312:1217–1224
35. Trebble TM, Wootton SA, Miles EA, Mullee M, Arden NK, Ballinger AB, Stroud MA, Burdge GC, Calder PC 2003 Prostaglandin E2 production and T cell function after fish-oil supplementation: response to antioxidant cosupplementation. *Am J Clin Nutr* 78:376–382
36. Simopoulos AP 1991 Omega-3 fatty acids in health and disease and in growth and development. *Am J Clin Nutr* 54:438–463
37. Broadfield EC, McKeever TM, Whitehurst A, Lewis SA, Lawson N, Britton J, Fogarty A 2004 A case-control study of dietary and erythrocyte membrane fatty acids in asthma. *Clin Exp Allergy* 34:1232–1236
38. Stoney RM, Woods RK, Hosking CS, Hill DJ, Abramson MJ, Thien FC 2004 Maternal breast milk long-chain n-3 fatty acids are associated with increased risk of atopy in breastfed infants. *Clin Exp Allergy* 34:194–200
39. Karlsson H, Hessel C, Rudin A 2002 Innate immune responses of human neonatal cells to bacteria from the normal gastrointestinal flora. *Infect Immun* 70:6688–6696
40. Filipp D, Alizadeh-Khiavi K, Richardson C, Palma A, Paredes N, Takeuchi O, Akira S, Julius M 2001 Soluble CD14 enriched in colostrum and milk induces B cell growth and differentiation. *Proc Natl Acad Sci U S A* 98:603–608
41. Isolauri E, Salminen S 2005 Probiotics, gut inflammation and barrier function. *Gastroenterol Clin North Am* 34:437–450
42. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R 2004 Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. *Cell* 118:229–241
43. Rinne M, Kalliomäki M, Arvilommi H, Salminen S, Isolauri E 2005 Effect of probiotics and breastfeeding on the *Bifidobacterium* and *Lactobacillus/Enterococcus* microbiota and humoral immune responses. *J Pediatr* 147:186–191